---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-26-000018"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:33:38.484494+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q1 revenue $374.8M (+15.6% YoY); net income $32.6M; no guidance due to pending BSX acquisition

## Summary
- Revenue $374.8M, up 15.6% YoY; thrombectomy $253.9M (+12.1%), embolization & access $120.8M (+23.8%).
- Gross margin 67.6% (+1.0 pp); operating income $38.2M; net income $32.6M.
- Operating expenses include $9.4M acquisition-related costs for pending Boston Scientific deal.
- No FY2026 guidance provided due to pending acquisition by Boston Scientific (NYSE: BSX).

## SEC filing metadata
- accession: 0001321732-26-000018
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000018/0001321732-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000018/pen-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-26-000018
- JSON: https://secwatch.observer/filing/0001321732-26-000018.json
- Plain text: https://secwatch.observer/filing/0001321732-26-000018.txt

## Source-grounded claims
- claim_id: 4506dfa7f1524bfe14891b5175b0ddf5c2220939
  claim: Penumbra Inc reported first quarter ended March 31, 2026 results: revenue $374.8 million, net income $32.6 million.
  evidence_excerpt: Penumbra, Inc. Reports First Quarter 2026 Financial Results ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. • Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. • Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. • Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. • Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. • Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pendin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000018/0001321732-26-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.